Abstract: A mask having an inner surface facing a wearer and an outer surface located opposite to the inner surface has first to fourth filters. The first filter is disposed on the outer surface of the mask and has air permeability and a water absorption capacity of 100% or more and less than 1000%. The second filter is layered on the first filter on the side of the inner surface of the mask and has air permeability and a water absorption capacity of less than 30%. The third filter is layered on the second filter on the side of the inner surface of the mask and is formed of an electret filter having air permeability and a water absorption capacity of less than 50%. The fourth filter is disposed on the inner surface of the mask and has air permeability.

Abstract: A mask having an inner surface facing a wearer and an outer surface located opposite to the inner surface has first to fourth filters. The first filter is disposed on the outer surface of the mask and has air permeability and a water absorption capacity of 100% or more and less than 1000%. The second filter is layered on the first filter on the side of the inner surface of the mask and has air permeability and a water absorption capacity of less than 30%. The third filter is layered on the second filter on the side of the inner surface of the mask and is formed of an electret filter having air permeability and a water absorption capacity of less than 50%. The fourth filter is disposed on the inner surface of the mask and has air permeability.

Abstract: The objective/problem addressed by the present invention is to provide a novel technique pertaining to theaflavins synthesis. The present invention pertains to: a theaflavins synthesis catalyst characterized in having a base comprising an inorganic material, and metal nanoparticles anchored to the base, said particles measuring 0.5-100 nm in diameter; and a theaflavins synthesis method in which the catalyst is used.

Abstract: The objective/problem addressed by the present invention is to provide a novel technique pertaining to theaflavins synthesis. The present invention pertains to: a theaflavins synthesis catalyst characterized in having a base comprising an inorganic material, and metal nanoparticles anchored to the base, said particles measuring 0.5-100 nm in diameter; and a theaflavins synthesis method in which the catalyst is used.

Abstract: [Problem] To provide a bactericidal composition for bacterial skin disease against which it is difficult for bacteria that cause bacterial skin disease to acquire drug resistance. [Solution] A bactericidal composition for bacterial skin disease that is characterized by including silver iodide in the form of nanoparticles having a particle size of 1-100 nm, inclusive, iodide ions, a water-soluble polymer, and an organic acid having a carboxyl group, and/or a salt of said acid, wherein the molar ratio of silver to iodide ions in the silver iodide is 1:1-1:1000.

Abstract: [Problem] The present invention provides a novel pathological marker of angiitis which serves as an alternative to MPO-ANCAs. [Means for Solution] According to one embodiment of the present invention, a method for testing angiitis which includes a step of detecting an antibody specifically recognizing a moesin in a biological sample is provided. In addition, according to another embodiment of the present invention, a reagent for testing angiitis which contains a substance that detects an antibody specifically recognizing a moesin in a biological sample is provided.

Abstract: [Problem] The present invention provides a novel pathological marker of angiitis which serves as an alternative to MPO-ANCAs. [Means for Solution]According to one embodiment of the present invention, a method for testing angiitis which includes a step of detecting an antibody specifically recognizing a moesin in a biological sample is provided. In addition, according to another embodiment of the present invention, a reagent for testing angiitis which contains a substance that detects an antibody specifically recognizing a moesin in a biological sample is provided.

Abstract: The present invention relates to the rigidity of a backlight chassis and is applicable to a liquid crystal display device including a backlight chassis and a light source located in the backlight chassis. A liquid crystal display device according to the present invention includes a backlight chassis (24), located to face a rear surface of a liquid crystal panel (10), for supporting a light source (22) for illuminating the rear surface of the liquid crystal panel (10). The backlight chassis (24) is a substantively flat plate-like member with upright peripheral portions (24a through 24d), and includes grooves (71 through 74) in a first area (A1) and a second area (A2), which are separated from each other by a border line (L) set on the backlight chassis (24). According to the present invention, the entirety of the backlight chassis is unlikely to be deflected.

Abstract: The present invention relates to the rigidity of a backlight chassis and is applicable to a liquid crystal display device including a backlight chassis and a light source located in the backlight chassis. A liquid crystal display device according to the present invention includes a backlight chassis (24), located to face a rear surface of a liquid crystal panel (10), for supporting a light source (22) for illuminating the rear surface of the liquid crystal panel (10). The backlight chassis (24) is a substantively flat plate-like member with upright peripheral portions (24a through 24d), and includes grooves (71 through 74) in a first area (A1) and a second area (A2), which are separated from each other by a border line (L) set on the backlight chassis (24). According to the present invention, the entirety of the backlight chassis is unlikely to be deflected.